ALKERMES PLC (ALKS) Fundamental Analysis & Valuation

NASDAQ:ALKS • IE00B56GVS15

Current stock price

29.37 USD
+0.97 (+3.42%)
At close:
29.34 USD
-0.03 (-0.1%)
After Hours:

This ALKS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. ALKS Profitability Analysis

1.1 Basic Checks

  • In the past year ALKS was profitable.
  • In the past year ALKS had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: ALKS reported negative net income in multiple years.
  • ALKS had a positive operating cash flow in each of the past 5 years.
ALKS Yearly Net Income VS EBIT VS OCF VS FCFALKS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.72%, ALKS belongs to the top of the industry, outperforming 93.45% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 13.28%, ALKS belongs to the top of the industry, outperforming 93.06% of the companies in the same industry.
  • ALKS's Return On Invested Capital of 10.90% is amongst the best of the industry. ALKS outperforms 94.03% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ALKS is in line with the industry average of 18.95%.
  • The 3 year average ROIC (18.21%) for ALKS is well above the current ROIC(10.90%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROIC 10.9%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ALKS Yearly ROA, ROE, ROICALKS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • ALKS has a better Profit Margin (16.37%) than 92.49% of its industry peers.
  • The Operating Margin of ALKS (17.21%) is better than 93.06% of its industry peers.
  • ALKS's Gross Margin of 86.69% is amongst the best of the industry. ALKS outperforms 88.63% of its industry peers.
  • ALKS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
ALKS Yearly Profit, Operating, Gross MarginsALKS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

7

2. ALKS Health Analysis

2.1 Basic Checks

  • ALKS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for ALKS has been increased compared to 1 year ago.
  • Compared to 5 years ago, ALKS has more shares outstanding
  • ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALKS Yearly Shares OutstandingALKS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ALKS Yearly Total Debt VS Total AssetsALKS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 5.44 indicates that ALKS is not in any danger for bankruptcy at the moment.
  • ALKS has a better Altman-Z score (5.44) than 75.14% of its industry peers.
  • ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.44
ROIC/WACC1.42
WACC7.67%
ALKS Yearly LT Debt VS Equity VS FCFALKS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 3.55 indicates that ALKS has no problem at all paying its short term obligations.
  • ALKS has a Current ratio (3.55) which is comparable to the rest of the industry.
  • A Quick Ratio of 3.19 indicates that ALKS has no problem at all paying its short term obligations.
  • ALKS's Quick ratio of 3.19 is on the low side compared to the rest of the industry. ALKS is outperformed by 60.31% of its industry peers.
Industry RankSector Rank
Current Ratio 3.55
Quick Ratio 3.19
ALKS Yearly Current Assets VS Current LiabilitesALKS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

5

3. ALKS Growth Analysis

3.1 Past

  • The earnings per share for ALKS have decreased strongly by -40.76% in the last year.
  • ALKS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 31.92% yearly.
  • The Revenue has decreased by -5.25% in the past year.
  • Measured over the past years, ALKS shows a small growth in Revenue. The Revenue has been growing by 7.28% on average per year.
EPS 1Y (TTM)-40.76%
EPS 3Y71.6%
EPS 5Y31.92%
EPS Q2Q%-72.38%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%

3.2 Future

  • Based on estimates for the next years, ALKS will show a very strong growth in Earnings Per Share. The EPS will grow by 31.80% on average per year.
  • The Revenue is expected to grow by 11.16% on average over the next years. This is quite good.
EPS Next Y-135.86%
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%
EPS Next 5Y31.8%
Revenue Next Year22.19%
Revenue Next 2Y13.07%
Revenue Next 3Y10.9%
Revenue Next 5Y11.16%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALKS Yearly Revenue VS EstimatesALKS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
ALKS Yearly EPS VS EstimatesALKS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6

4

4. ALKS Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 17.08, the valuation of ALKS can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of ALKS indicates a rather cheap valuation: ALKS is cheaper than 94.61% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.61, ALKS is valued a bit cheaper.
  • The Forward Price/Earnings Ratio is negative for ALKS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 17.08
Fwd PE N/A
ALKS Price Earnings VS Forward Price EarningsALKS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

  • 94.22% of the companies in the same industry are more expensive than ALKS, based on the Enterprise Value to EBITDA ratio.
  • ALKS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ALKS is cheaper than 97.50% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.19
EV/EBITDA 14.03
ALKS Per share dataALKS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • The decent profitability rating of ALKS may justify a higher PE ratio.
  • A cheap valuation may be justified as ALKS's earnings are expected to decrease with -2.65% in the coming years.
PEG (NY)N/A
PEG (5Y)0.53
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%

0

5. ALKS Dividend Analysis

5.1 Amount

  • No dividends for ALKS!.
Industry RankSector Rank
Dividend Yield 0%

ALKS Fundamentals: All Metrics, Ratios and Statistics

ALKERMES PLC

NASDAQ:ALKS (3/25/2026, 7:11:17 PM)

After market: 29.34 -0.03 (-0.1%)

29.37

+0.97 (+3.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-29
Inst Owners109.8%
Inst Owner Change2.03%
Ins Owners1.6%
Ins Owner Change5.8%
Market Cap4.89B
Revenue(TTM)1.48B
Net Income(TTM)241.66M
Analysts81.67
Price Target44.69 (52.16%)
Short Float %11.17%
Short Ratio8.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.45%
Min EPS beat(2)-16.95%
Max EPS beat(2)59.84%
EPS beat(4)3
Avg EPS beat(4)31.82%
Min EPS beat(4)-16.95%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)15.4%
EPS beat(12)7
Avg EPS beat(12)24.7%
EPS beat(16)10
Avg EPS beat(16)139.34%
Revenue beat(2)1
Avg Revenue beat(2)3.48%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)8.51%
Revenue beat(4)2
Avg Revenue beat(4)4.47%
Min Revenue beat(4)-1.55%
Max Revenue beat(4)12.13%
Revenue beat(8)3
Avg Revenue beat(8)2.64%
Revenue beat(12)6
Avg Revenue beat(12)3.42%
Revenue beat(16)9
Avg Revenue beat(16)2.75%
PT rev (1m)0%
PT rev (3m)-0.14%
EPS NQ rev (1m)-476.76%
EPS NQ rev (3m)-596.9%
EPS NY rev (1m)-141.15%
EPS NY rev (3m)-140.46%
Revenue NQ rev (1m)3.82%
Revenue NQ rev (3m)0.52%
Revenue NY rev (1m)-0.7%
Revenue NY rev (3m)-1.5%
Valuation
Industry RankSector Rank
PE 17.08
Fwd PE N/A
P/S 3.32
P/FCF 10.19
P/OCF 9.4
P/B 2.69
P/tB 2.82
EV/EBITDA 14.03
EPS(TTM)1.72
EY5.86%
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)2.88
FCFY9.81%
OCF(TTM)3.12
OCFY10.64%
SpS8.86
BVpS10.92
TBVpS10.41
PEG (NY)N/A
PEG (5Y)0.53
Graham Number20.55
Profitability
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROCE 13.07%
ROIC 10.9%
ROICexc 15.63%
ROICexgc 16.66%
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
FCFM 32.55%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ROICexc(3y)43.15%
ROICexc(5y)N/A
ROICexgc(3y)50.12%
ROICexgc(5y)N/A
ROCE(3y)21.84%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 148.79%
Cap/Sales 2.74%
Interest Coverage 250
Cash Conversion 185.24%
Profit Quality 198.76%
Current Ratio 3.55
Quick Ratio 3.19
Altman-Z 5.44
F-Score6
WACC7.67%
ROIC/WACC1.42
Cap/Depr(3y)110.09%
Cap/Depr(5y)83%
Cap/Sales(3y)2.59%
Cap/Sales(5y)2.72%
Profit Quality(3y)136.19%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.76%
EPS 3Y71.6%
EPS 5Y31.92%
EPS Q2Q%-72.38%
EPS Next Y-135.86%
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%
EPS Next 5Y31.8%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%
Revenue Next Year22.19%
Revenue Next 2Y13.07%
Revenue Next 3Y10.9%
Revenue Next 5Y11.16%
EBIT growth 1Y-39.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.49%
EBIT Next 3Y26.34%
EBIT Next 5Y26.53%
FCF growth 1Y18.41%
FCF growth 3YN/A
FCF growth 5Y63.91%
OCF growth 1Y18.59%
OCF growth 3Y191.61%
OCF growth 5Y44.45%

ALKERMES PLC / ALKS Fundamental Analysis FAQ

What is the fundamental rating for ALKS stock?

ChartMill assigns a fundamental rating of 6 / 10 to ALKS.


What is the valuation status of ALKERMES PLC (ALKS) stock?

ChartMill assigns a valuation rating of 4 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.


Can you provide the profitability details for ALKERMES PLC?

ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.


Can you provide the expected EPS growth for ALKS stock?

The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -135.86% in the next year.